The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | Redefining second-line therapy in myeloma with CAR T-cell therapy
In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, briefly discusses the potential to redefine second-line therapy in multiple myeloma (MM) with CAR T-cell therapy. Prof. Einsele notes that CAR T-cell therapy has shown promise in inducing long-term disease-free survival in a subset of heavily pretreated patients, and hopes that moving this treatment to the second line will benefit an even larger percentage of patients. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we have the approval now for cilta-cel in patients that had received at least one line of therapy, including an IMID and PI, and an anti-CD38 antibody, and being lenalidomide-refractory. So this is the patient where we have now the approval to go ahead with CAR T-cell therapy. And we have actually seen that also in patients that are much more heavily pretreated, CAR T-cell therapy in a fraction of patients, it’s about 33% of patients, can induce long-term disease-free survival...
So we have the approval now for cilta-cel in patients that had received at least one line of therapy, including an IMID and PI, and an anti-CD38 antibody, and being lenalidomide-refractory. So this is the patient where we have now the approval to go ahead with CAR T-cell therapy. And we have actually seen that also in patients that are much more heavily pretreated, CAR T-cell therapy in a fraction of patients, it’s about 33% of patients, can induce long-term disease-free survival. So the hope is, if we move it now to the second line, that we have an even larger percentage of patients that we see to benefit long-term from this treatment. And there is a hope that we can, even in relapsed patients, get some patients to achieve long-term remission and cure for multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
